UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

The New England journal of medicine, 2022-09, Vol.387 (9), p.810-823

2022

Volltextzugriff (PDF)

Practical approaches to Bayesian sample size determination in non‐inferiority trials with binary outcomes

Statistics in medicine, 2023-04, Vol.42 (8), p.1127-1138

2023

Volltextzugriff (PDF)

Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions

BMC medicine, 2020-09, Vol.18 (1), p.286-286, Article 286

2020

Volltextzugriff (PDF)

Patients' priorities around drug-resistant tuberculosis treatment: A multi-national qualitative study from Mongolia, South Africa and Georgia

Global public health, 2023, Vol.18 (1), p.2234450-2234450

2023

Volltextzugriff (PDF)

Disseminating the research findings from the adolescents and adults living with Perinatal HIV (AALPHI) study: an approach from young people living with HIV

Research involvement and engagement, 2024-01, Vol.10 (1), p.9-9, Article 9

2024

Volltextzugriff (PDF)

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

BMC infectious diseases, 2018-07, Vol.18 (1), p.317-11, Article 317

2018

Volltextzugriff (PDF)

Formalising the induction of patient and public involvement contributors on trial oversight committees

Research involvement and engagement, 2021-06, Vol.7 (1), p.1-42, Article 42

2021

Volltextzugriff (PDF)

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

BMC pulmonary medicine, 2019-08, Vol.19 (1), p.152-9, Article 152

2019

Volltextzugriff (PDF)

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

The lancet respiratory medicine, 2019-12, Vol.7 (12), p.1048-1058

2019

Volltextzugriff (PDF)

Lung injury from e-cigarette use: a foul and pestilent congregation of vapours

BMJ case reports, 2020-11, Vol.13 (11), p.e237338

2020

Volltextzugriff (PDF)

Models and impact of patient and public involvement in studies carried out by the Medical Research Council Clinical Trials Unit at University College London: findings from ten case studies

Trials, 2016-07, Vol.17 (1), p.376-376, Article 376

2016

Volltextzugriff (PDF)

Rethinking intercurrent events in defining estimands for tuberculosis trials

Clinical trials (London, England), 2022-10, Vol.19 (5), p.522-533

2022

Volltextzugriff (PDF)

Erratum to: 'Models and impact of patient and public involvement in studies carried out by the Medical Research Council Clinical Trials Unit at University College London: findings from ten case studies'

Trials, 2016-09, Vol.17 (1), p.440, Article 440

2016

Volltextzugriff (PDF)

Bedaquiline: what might the future hold?

The Lancet. Microbe, 2024-07, p.100909, Article 100909

2024

Volltextzugriff (PDF)

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

The New England journal of medicine, 2019-03, Vol.380 (13), p.1201-1213

2019

Volltextzugriff (PDF)

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

BMC medicine, 2018-03, Vol.16 (1), p.46-10, Article 46

2018

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(12)
Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Clinical Trials
(7)
Tuberculosis
(7)
General & Internal Medicine
(6)
Hiv
(6)
Adult
(5)
Human Immunodeficiency Virus
(5)
Male
(5)
Medical Research
(5)
Medicine, General & Internal
(5)
Antitubercular Agents - Adverse Effects
(4)
Female
(4)
Patients
(4)
Research Design
(4)
Treatment Outcome
(4)
Adverse Events
(3)
Drug Dosages
(3)
Hiv Patients
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Practical approaches to Bayesian sample size determination in non‐inferiority trials with binary outcomes

Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions

Patients' priorities around drug-resistant tuberculosis treatment: A multi-national qualitative study from Mongolia, South Africa and Georgia

Disseminating the research findings from the adolescents and adults living with Perinatal HIV (AALPHI) study: an approach from young people living with HIV

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Formalising the induction of patient and public involvement contributors on trial oversight committees

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Lung injury from e-cigarette use: a foul and pestilent congregation of vapours

Models and impact of patient and public involvement in studies carried out by the Medical Research Council Clinical Trials Unit at University College London: findings from ten case studies

Rethinking intercurrent events in defining estimands for tuberculosis trials

Erratum to: 'Models and impact of patient and public involvement in studies carried out by the Medical Research Council Clinical Trials Unit at University College London: findings from ten case studies'

Bedaquiline: what might the future hold?

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Aktive Filter

Suchergebnisse filtern